- Home
- HOLO vs OTLK Comparison
HOLO vs OTLK Comparison
Compare HOLO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | OTLK |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HOLO | OTLK |
|---|---|---|
| Price | $2.75 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 621.7K | ★ 12.7M |
| Earning Date | 08-10-2023 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | $1,413,535.00 |
| Revenue This Year | N/A | $1,578.49 |
| Revenue Next Year | N/A | $153.58 |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | ★ 37.10 | N/A |
| 52 Week Low | $2.57 | $0.49 |
| 52 Week High | $103.60 | $3.39 |
Technical Indicators
Market Signals| Indicator | HOLO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 24.53 |
| Support Level | $2.66 | $0.51 |
| Resistance Level | $2.99 | $0.54 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 20.39 | 11.58 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.